Drug-eluting polymer implants in cancer therapy

Expert Opinion on Drug Delivery

Volumn 5, Issue 7, 2008, Pages 775-788

  Exner, Agata A ^a,b   Saidel, Gerald M ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Case Western Reserve University   (United States)

Author keywords

Adjuvant therapy; Biodegradable polymer implants; Cancer chemotherapy; Drug delivery; Image guided delivery; In situ forming depots; Mathematical modeling

Indexed keywords

ADRENALIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; COPOLYMER; DOXORUBICIN; LEUPRORELIN; LIPOSOME; MACROGOL; NIFEDIPINE; ONCOGEL; PACLITAXEL; POLYGLACTIN; POLYLACTIC ACID; POLYMER; PROPRANOLOL; THEOPHYLLINE;

BIODEGRADABILITY; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG RELEASE; DRUG TARGETING; GLASS TRANSITION TEMPERATURE; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; HYDROGEL; MATHEMATICAL MODEL; MICELLE; MINIMALLY INVASIVE SURGERY; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUSTAINED RELEASE FORMULATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; HUMANS; NEOPLASMS; POLYMERS;

EID: 48449103101     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.7.775     Document Type: Review

References (137)

1. Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman's The pharmacological basis of therapeutics. 10th edition. McGraw-Hill Professional; 2001
2. Pronzato P, Rondini M. First line chemotherapy of metastatic breast cancer. Ann Oncol 2006;17(Suppl 5):v165-68
3. Kramer M, Tomek S, Elandt K, et al. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer. J Urol 2007;177(6):2141-5; discussion 5
4. Aydiner A, Kiyik M, Cikrikcioglu S, et al. Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: a phase II study. Lung Cancer 2007;58(2):246-52
5. Waxman ES. Advances in chemotherapy for non-small cell lung cancer. Semin Oncol Nurs 2008;24(1):49-56
6. Clancy TE, Dixon E, Perlis R, et al. Hepatic arterial infusion after curative resection of colorectal cancer metastases: a meta-analysis of prospective clinical trials. J Gastrointest Surg 2005;9(2):198-206
7. Vogl T, Eichler K, Zangos S, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol 2007;133(3):177-84
8. Vogl TJ, Zangos S, Eichler K, et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 2007;17(4):1025-34
9. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30(1):6-25
10. Vogelbaum MA. Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J Neurooncol 2007;83(1):97-109
11. Sampson JH, Akabani G, Friedman AH, et al. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus 2006;20(4):E14
12. Krauze MT, Vandenberg SR, Yamashita Y, et al. Safety of real-time convection-enhanced delivery of liposomes to primate brain: a long-term retrospective. Exp Neurol 2008;210(2):638-44
13. Mamot C, Nguyen JB, Pourdehnad M, et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol 2004;68(1):1-9
14. Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med 2006;79(3-4):141-52
15. Poirier VJ, Thamm DH, Kurzman ID, et al. Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J Vet Intern Med 2002;16(6):726-31
16. Alakhov V, Klinski E, Li S, et al. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf B Biointerfaces 1999;16:113-34
17. Gref R, Minamitake Y, Peracchia MT, et al. Biodegradable long-circulating polymeric nanospheres. Science 1994;263(5153):1600-3
18. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2006;58(14):1532-55
19. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res 2007;24(1):1-16
20. Torchilin VP. Application of nanomedical approaches in experimental and clinical oncology. Anticancer Agents Med Chem 2006;6(6):501
21. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6(8):583-92
22. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001;46(1-3):149-68
23. Jam RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271(1):58-65
24. Swanson GP. Management of locally advanced prostate cancer: past, present, future. J Urol 2006;176(6 Pt 2):S34-41
25. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296(19):2329-35
26. Weinberg BD, Blanco E, Gao J. Polymer implants for intratumoral drug delivery and cancer therapy. J Pharm Sci 2007
27. Saltzman WM, Fung LK. Polymeric implants for cancer chemotherapy. Adv Drug Deliv Rev 1997;26(2-3):209-30
28. Coleman DL, King RN, Andrade JD. The foreign body reaction: a chronic inflammatory response. J Biomed Mater Res 1974;8(5):199-211
29. Hetrick EM, Prichard HL, Klitzman B, Schoenfisch MH. Reduced foreign body response at nitric oxide-releasing subcutaneous implants. Biomaterials 2007;28(31):4571-80
30. James SJ, Pogribna M, Miller BJ, et al. Characterization of cellular response to silicone implants in rats: implications for foreign-body carcinogenesis. Biomaterials 1997;18(9):667-75
31. Jam RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000;21(23):2475-90
32. von Burkersrodaa F, Schedlb L, Gopferich A. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 2002;23:4221-31
33. Athanasiou KA, Niederauer GG, Agrawal CM. Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/ polyglycolic acid copolymers. Biomaterials 1996;17(2):93-102
34. Fournier E, Passirani C, Montero-Menei CN, Benoit JP. Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility. Biomaterials 2003;24(19):3311-31
35. Chen FA, Kuriakose MA, Thou MX, et al. Biodegradable polymer-mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model. Head Neck 2003;25(7):554-60
36. Monga SP, Wadleigh R, Sharma A, et al. Intratumoral therapy of cisplatin/ epinephrine injectable gel for palliation in patients with obstructive esophageal cancer. Am J Clin Oncol 2000;23(4):386-92
37. Yapp DT, Lloyd DK, Zhu J, Lehnert SM. The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin. Int J Radiat Oncol Biol Phys 1998;42(2):413-20
38. Burris HA III, Vogel CL, Castro D, et al. Intratumoral cisplatin/ epinephrine-injectable gel as a palliative treatment for accessible solid tumors: a multicenter pilot study. Otolaryngol Head Neck Surg 1998;118(4):496-503
39. Castro DJ, Sridhar KS, Garewal HS, et al. Intratumoral cisplatin/ epinephrine gel in advanced head and neck cancer: a multicenter, randomized, double-blind, phase III study in North America. Head Neck 2003;25(9):717-31
40. Fung LK, Shin M, Tyler B, et al. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm Res 1996;13(5):671-82
41. Gao J, Qian F, Szymanski-Exner A, et al. In vivo drug distribution dynamics in thermoablated and normal rabbit livers from biodegradable polymers. J Biomed Mater Res 2002;62(2):308-14
42. Krupka TM, Weinberg BD, Ziats NP, et al. Injectable polymer depot combined with radiofrequency ablation for treatment of experimental carcinoma in rat. Invest Radiol 2006;41(12):890-7
43. Qian F, Szymanski A, Gao J. Fabrication and characterization of controlled release poly(D,L-lactide-co-glycolide) millirods. J Biomed Mater Res 2001;55(4):512-22
44. Qian F, Stowe N, Liu EH, et al. Quantification of in vivo doxorubicin transport from PLGA millirods in thermoablated rat livers. J Control Release 2003;91(1-2):157-66
45. Qian F, Stowe N, Saidel GM, Gao J. Comparison of doxorubicin concentration profiles in radiofrequency-ablated rat livers from sustained- and dual-release PLGA millirods. Pharm Res 2004;21(3):394-9
46. Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998;58(4):672-84
47. Strasser JF, Fung LK, Eller S, et al. Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants. J Pharmacol Exp Ther 1995;275(3):1647-55
48. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: an overview. Eur J Pharm Biopharm 2004;58(2):445-55
49. Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Release 2002;80(1-3):9-28
50. McHugh AJ. The role of polymer membrane formation in sustained release drug delivery systems. J Control Release 2005;109(1-3):211-21
51. Berges R, Bello U. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin 2006;22(4):649-55
52. Cox MC, Scripture CD, Figg WD. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain? Expert Rev Anticancer Ther 2005;5(4):605-11
53. Perez-Marrero R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447-57
54. Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 2003;61(2 Suppl 1):25-31
55. Schulman C, Alcaraz A, Berges R, et al. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer. BJU Int 2007;100(Suppl 1):1-5
56. Packhaeuser CB, Kissel T. On the design of in situ forming biodegradable parenteral depot systems based on insulin loaded dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-co-glycolide) nanoparticles. J Control Release 2007;123(2):131-40
57. Graham PD, Brodbeck KJ, McHugh AJ. Phase Inversion dynamics of PLGA solutions related to drug delivery. J Control Release 1999;58(2):233-45
58. Brodbeck KJ, DesNoyer JR, McHugh AJ. Phase Inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. J Control Release 1999;62(3):333-44
59. Brodbeck KJ, Pushpala S, McHugh AJ. Sustained release of human growth hormone from PLGA solution depots. Pharm Res 1999;16(12):1825-9
60. Raman C, McHugh AJ. A model for drug release from fast phase inverting injectable solutions. J Control Release 2005;102(1):145-57
61. DesNoyer JR, McHugh AJ. The effect of Pluronic on the protein release kinetics of an injectable drug delivery system. J Control Release 2003;86(1):15-24
62. Bohorquez M, Koch C, Trygstad T, Pandit N. A study of the temperature-dependent micellization of Pluronic F127. J Colloid Interface Sci 1999;216(1):34-40
63. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002;54(5):759-79
64. Batrakova EV, Li S, Vinogradov SV, et al. Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 2001;299(2):483-93
65. Matthes K, Mino-Kenudson M, Sahani DV, et al. EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in the porcine pancreas (with video). Gastrointest Endosc 2007;65(3):448-53
66. Yu L, Chang GT, Zhang H, Ding JD. Injectable block copolymer hydrogels for sustained release of a PEGylated drug. Int J Pharm 2008;348(1-2):95-106
67. Ishihara M, Obara K, Nakamura S, et al. Chitosan hydrogel as a drug delivery carrier to control angiogenesis. J Artif Organs 2006;9(1):8-16
68. Balakrishnan B, Jayakrishnan A. Self-cross-linking biopolymers as injectable in situ forming biodegradable scaffolds. Biomaterials 2005;26(18):3941-51
69. Jan JP, Modi S, Kumar N. Hydroxy fatty acid based polyanhydride as drug delivery system: Synthesis, characterization, in vitro degradation, drug release, and biocompatibiity. J Biomed Mater Res A 2007;84A(3):740-52
70. Loh XJ, Gob SH, Li J. New biodegradable thermogelling copolymers having very low gelation concentrations. Biomacromolecules 2007;8(2):585-93
71. Mak M, Fung L, Strasser JF, Saltzman WM. Distribution of drugs following controlled delivery to the brain interstitium. J Neurooncol 1995;26(2):91-102
72. Dupuy DE. Tumor ablation: treatment and palliation using image-guided therapy. Oncology (Williston Park) 2005;19(11 Suppl 4):4-5
73. Lange T, Hunerbein M, Eulenstein S, et al. Development of navigation systems for image-guided laparoscopic tumor resections in liver surgery. Recent Results Cancer Res 2006;167:13-36
74. Ruhl R, Ricke J. Image-guided micro-therapy for tumor ablation: from thermal coagulation to advanced irradiation techniques. Onkologie 2006;29(5):219-24
75. Shirato H, Shimizu S, Kitamura K, Onimaru R. Organ motion in image-guided radiotherapy: lessons from real-time tumor-tracking radiotherapy. Int J Clin Oncol 2007;12(1):8-16
76. Haaga JR, Exner AA, Wang Y, et al. Combined tumor therapy by using radiofrequency ablation and 5-FU-laden polymer implants: evaluation in rats and rabbits. Radiology 2005;237(3):911-8
77. Marescaux J, Solerc L. Image-guided robotic surgery. Semin Laparosc Surg 2004;11(2):113-22
78. Tsekos NV, Khanicheh A, Christoforou E, Mavroidis C. Magnetic resonance-compatible robotic and mechatronics systems for image-guided interventions and rehabilitation: a review study. Ann Rev Biomed Eng 2007;9:351-87
79. Weinberg BD, Patel RB, Exner AA, et al. Modeling doxorubicin transport to improve intratumoral drug delivery to RF ablated tumors. J Control Release 2007;124(1-2):11-9
80. Choy G, Choyke P, Libutti SK. Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging 2003;2(4):303-12
81. Choy G, O'Connor S, Diehn FE, et al. Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques 2003;35(5):1022-6, 8-30
82. Licha K, Olbrich C. Optical imaging in drug discovery and diagnostic applications. Adv Drug Deliv Rev 2005;57(8):1087-108
83. Richardson JC, Bowtell RW, Mader K, Melia CD. Pharmaceutical applications of magnetic resonance imaging (MRI). Adv Drug Deliv Rev 2005;57(8):1191-209
84. Rudin M. Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions. Eur Radiol 2007;17(10):2441-57
85. Rudin M, Rausch M, Stoeckli M. Molecular imaging in drug discovery and development: potential and limitations of nonnuclear methods. Mol Imaging Biol 2005;7(1):5-13
86. Swartz H. Seeing is believing - visualizing drug delivery in vitro and in vivo. Adv Drug Deliv Rev 2005;57(8):1085-6
87. Tang JS, Choy G, Bernardo M, et al. Dynamic contrast-enhanced magnetic resonance imaging in the assessment of early response to tumor necrosis factor alpha in a colon carcinoma model. Invest Radiol 2006;41(9):691-6
88. Gupta N, Price PM, Aboagye EO. PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur J Cancer 2002;38(16):2094-107
89. Salem KA, Szymanski-Exner A, Lazebnik RS, et al. X-ray computed tomography methods for in vivo evaluation of local drug release systems. IEEE Trans Med Imaging 2002;21(10):1310-6
90. Szymanski-Exner A, Stowe NT, Salem K, et al. Noninvasive monitoring of local drug release using X-ray computed tomography: optimization and in vitro/in vivo validation. J Pharm Sci 2003;92(2):289-96
91. Ryu WH, Vyakarnam M, Greco RS, et al. Fabrication of multi-layered biodegradable drug delivery device based on micro-structuring of PLGA polymers. Biomed Microdevices 2007;9(6):845-53
92. Jain RA, Rhodes CT, Railkar AM, et al. Comparison of various injectable protein-loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices: in situ-formed implant versus in situ-formed microspheres versus isolated microspheres. Pharm Dev Technol 2000;5(2):201-7
93. Krupka TM, Weinberg BD, Wu H, et al. Effect of intratumoral injection of carboplatin combined with pluronic P85 or L61 on experimental colorectal carcinoma in rats. Exp Biol Med (Maywood) 2007;232(7):950-7
94. Exner AA, Krupka TM, Scherrer K, Teets JM. Enhancement of carboplatin toxicity by Pluronic block copolymers. J Control Release 2005;106(1-2):188-97
95. Kabanov AV, Batrakova EV, Miller DW. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv Drug Deliv Rev 2003;55(1):151-64
96. Batrakova LV, Li S, Alakhov VY, et al. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther 2003;304(2):845-54
97. Gao Z, Kennedy AM, Christensen DA, Rapoport NY. Drug-loaded nano/ microbubbles for combining ultrasonography and targeted chemotherapy. Ultrasonics 2007; 19
98. Gao ZG, Fain HD, Rapoport N. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J Control Release 2005;102(1):203-22
99. Rapoport NY, Christensen DA, Fain HD, et al. Ultrasound-triggered drug targeting of tumors in vitro and in vivo. Ultrasonics 2004;42(1-9):943-50
100. Reich G. Ultrasound-induced degradation of PLA and PLGA during microsphere processing: influence of formulation variables. Eur J Pharm Biopharm 1998;45(2):165-71
101. Koning GA, Krijger GC. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery. Anticancer Agents Med Chem 2007;7(4):425-40
102. Deckers R, Rome C, Moonen CT. The role of ultrasound and magnetic resonance in local drug delivery. J Magn Reson Imaging 2008;27(2):400-9
103. Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 2003;100(23):13549-54
104. Fernandez-Pachecoa R, Marquinab C, Valdiviaa J, et al. Magnetic nanoparticles for local drug delivery using magnetic implants. J Magnetism Magnetic Mater 2007;311:318-22
105. Sershen S, West J. Implantable, polymeric systems for modulated drug delivery. Adv Drug Deliv Rev 2002;54(9):1225-35
106. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 2001;48(2-3):139-57
107. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 1961;50:874-5
108. Kill S, Dam-Johansen K. Controlled drug delivery from swellable hydroxypropylmethylcellulose matrices: model-based analysis of observed radial front movements. J Control Release 2003;90(1):1-21
109. Grassi M, Voinovich D, Franceschinis E, et al. Theoretical and experimental study on theophylline release from stearic acid cylindrical delivery systems. J Control Release 2003;92(3):275-89
110. Wu N, Wang LS, Tan DC, et al. Mathematical modeling and in vitro study of controlled drug release via a highly swellable and dissoluble polymer matrix: polyethylene oxide with high molecular weights. J Control Release 2005;102(3):569-81
111. Wang F, Saidel GM, Gao J. A mechanistic model of controlled drug release from polymer millirods: effects of excipients and complex binding. J Control Release 2007;119(1):111-20
112. Frenning G, Stromme M. Drug release modeled by dissolution, diffusion, and immobilization. Int J Pharm 2003;250(1):137-45
113. Hombreiro-Perez M, Siepmann J, Zinutti C, et al. Non-degradable microparticles containing a hydrophilic and/or a lipophilic drug: preparation, characterization and drug release modeling. J Control Release 2003;88(3):413-28
114. Zhang M, Yang Z, Chow LL, Wang CH. Simulation of drug release from biodegradable polymeric microspheres with bulk and surface erosions. J Pharm Sci 2003;92(10):2040-56
115. Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007;12(1-2):34-42
116. Crocetti L, Lencioni R, Bozzi E, et al. Lung radiofrequency ablation: in vivo experimental study with low-perfusion-rate multitined electrodes. Cardiovasc Intervent Radiol 2008
117. Kim SK, Gu MS, Hong HP, et al. CT findings after radiofrequency ablation in rabbit livers: comparison of internally cooled electrodes, perfusion electrodes, and internally cooled perfusion electrodes. J Vasc Interv Radiol 2007;18(11):1417-27
118. Goldberg SN, Gazelle GS. Radiofrequency tissue ablation: physical principles and techniques for increasing coagulation necrosis. Hepatogastroenterology 2001;48(38):359-67
119. El-Deiry WS, Sigman CC, Kelloff GJ. Imaging and oncologic drug development. J Clin Oncol 2006;24(20):3261-73
120. Sok JC, Kuriakose MA, Mahajan VB, et al. Tissue-specific gene expression of head and neck squamous cell carcinoma in vivo by complementary DNA microarray analysis. Arch Otolaryngol Head Neck Surg 2003;129(7):760-70
121. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996;271(5252):1079-80
122. Altucci L, Balducci L, Irminger-Finger I. Cancer therapy: new drugs are emerging based on molecular targeting but still many challenges. Int J Biochem Cell Biol 2007;39(7-8):1278-9
123. Kumar R. Commentary: targeting colorectal cancer through molecular biology. Semin Oncol 2005;32(6 Suppl 9):S37-9
124. DeNardo SJ. Combined molecular targeting for cancer therapy: a new paradigm in need of molecular imaging. J Nucl Med 2006;47(1):4-5
125. Vanhoefer U. Molecular mechanisms and targeting of colorectal cancer. Semin Oncol 2005;32(6 Suppl 8):7-10
126. Xiong HQ. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 2004;54(Suppl 1):S69-77
127. Minko T, Dharap SS, Pakunlu RI, Wang Y. Molecular targeting of drug delivery systems to cancer. Curr Drug Targets 2004;5(4):389-406
128. Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003;94(1):15-21
129. Balleine RL, Kefford RF. Targeting molecular mechanisms in cancer. ANZ J Surg 2002;72(10):760-3
130. Tlsty TD. A molecular blueprint for targeting cancer? Nat Genet 1999;21(1):64-5
131. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
132. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64(11):3731-6
133. Goldberg SN, Girnan GD, Lukyanov AN, et al. Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology 2002;222(3):797-804
134. Szymanski-Exner A, Gallacher A, Stowe NT, et al. Local carboplatin delivery and tissue distribution in livers after radiofrequency ablation. J Biomed Mater Res A 2003;67(2):510-6
135. Szymanski-Exner A, Stowe NT, Lazebnik RS, et al. Noninvasive monitoring of local drug release in a rabbit radiofrequency (RF) ablation model using X-ray computed tomography. J Control Release 2002;83(3):415-25
136. Weinberg BD, Ai H, Blanco E, et al. Antitumor efficacy and local distribution of doxorubicin via intratumoral delivery from polymer millirods. J Biomed Mater Res A 2007;81(1):161-70
137. Weinberg BD, Blanco E, Lempka SF, et al. Combined radiofrequency ablation and doxorubicin-eluting polymer implants for liver cancer treatment. J Biomed Mater Res A 2007;81(1):205-13